Fig. 2From: Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort studyKaplan-Meier plot of time to discontinuation/switching among patients with IPF treated with pirfenidone or nintedanibBack to article page